SCHEMBL5430306

SCHEMBL5430306

CC(C)(C)NC(=O)Nc1ccc2c(c1)c(Cl)nn2CC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ AR P10275 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ SSTR4 P31391 1/20 0.41
▸ CSK P41240 1/20 0.41
▸ ZAP70 P43403 1/20 0.41
▸ KDM4C Q9H3R0 2/20 0.40
▸ POLB P06746 1/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5436150 0.96 KDM4E (0.43) CFDKDM4EHTTARNPC1
SCHEMBL5306381 0.84 CYP3A4 (0.45) KDM4ENPC1RAB9AGAAALDH1A1
SCHEMBL27713903 0.83 KDM4C (0.43) CFDARNPC1SSTR4KDM4C
SCHEMBL14360901 0.83 AR (0.45) ARSSTR4KDM4CKMT2ACNR1
SCHEMBL14361036 0.79 L3MBTL1 (0.44) HTTRAB9AGAAALDH1A1HPGD
SCHEMBL27693955 0.79 OPRM1 (0.43) CFDARNPC1KDM4CCNR1
SCHEMBL5303414 0.79 TYK2 (0.49) NPC1RAB9AHPGDSMN1; SMN2KDM4C
SCHEMBL14361085 0.78 TSHR (0.42) KDM4EGAAALDH1A1TP53HPGD
SCHEMBL5309570 0.78 KDM4E (0.42) KDM4EHTTNPC1ALDH1A1HPGD
SCHEMBL14361090 0.77 HPGD (0.45) KDM4EGAAALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265325-A1 Nitro Indazole Derivatives NOS3, CYP3A43, NOS2 CFD 4158/4885KDM4E 3385/4885HTT 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback